Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies.

ABSTRACT: Pancreatic cancer remains largely an incurable disease necessitating the development of novel therapeutic approaches. Adoptive immunotherapy using chimeric antigen receptor (CAR)-transduced T cells represents an alternative treatment with curative potential. We present an overview of the engineering of novel CARs targeting prostate stem cell antigen (PSCA), implications for the development of immunotherapies, and potential strategies to circumvent on-target/off-tumor toxicities.

SUBMITTER: Abate-Daga D 

PROVIDER: S-EPMC4108460 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature